1.Updates of Primary Lung Cancer Diagnosis and Treatment Norms (2015 Edition) radiation therapy
Journal of Chinese Physician 2016;18(6):801-804
Primary lung cancer is one of the most common malignant tumors in China.The 2015 Edition of primary lung cancer diagnosis and treatment norms was updated based on 2010 Edition.This 2015 edition was published by the National Health and Family Planning Commission,which has referenced to the international authority of the lung cancer treatment guidelines and the actual situation of China.This paper mainly introduces the new content of lung cancer radiotherapy,including radical radiotherapy,palliative radiotherapy,adjuvant radiotherapy and preventive radiotherapy.
2.Effects of c-jun on hCG-induced testosterone secretion of rat Leydig cells in vitro.
Shuanghu YUAN ; Sifan XU ; Xinhua YANG ; Xiuqing LIU ; Junfang HAO ; Ming QIAN
National Journal of Andrology 2004;10(5):345-350
OBJECTIVETo investigate the effects of c-jun on hCG-induced testosterone secretion in isolated rat Leydig cells by antisense oligodeoxynucleotides(ASODNs).
METHODSc-jun ASODNs were used to antagonise the effects of c-jun, hCG was used to induce the testosterone secretion of LC cultured in vitro and testosterone was measured by radioimmunoassay.
RESULTSThe testosterone secretion of LC in vitro could be induced by hCG, which was a good model for the functional study of LC. c-jun ASODNs decreased the hCG-induced testosterone secretion of LC in a dose-dependent manner(P < 0.05).
CONCLUSIONIt is suggested that c-jun proto-oncogene enhances the testosterone secretion of LC.
Animals ; Cells, Cultured ; Chorionic Gonadotropin ; pharmacology ; Dose-Response Relationship, Drug ; Leydig Cells ; secretion ; Male ; Oligonucleotides, Antisense ; pharmacology ; Proto-Oncogene Proteins c-jun ; physiology ; Rats ; Rats, Sprague-Dawley ; Testosterone ; secretion
3.Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation
Yuchun WEI ; Chuqing WEI ; Liang CHEN ; Ning LIU ; Qiuxiang OU ; Jiani C. YIN ; Jiaohui PANG ; Zhenhao FANG ; Xue WU ; Xiaonan WANG ; Dianbin MU ; Yang SHAO ; Jinming YU ; Shuanghu YUAN
Cancer Research and Treatment 2022;54(4):1209-1218
Purpose:
Neoadjuvant therapy modality can increase the operability rate and mitigate pathological risks in locally advanced cervical cancer, but treatment response varies widely. It remains unclear whether genetic alterations correlate with the response to neoadjuvant therapy and disease-free survival (DFS) in locally advanced cervical cancer.
Materials and Methods:
A total of 62 locally advanced cervical cancer (stage IB-IIA) patients who received neoadjuvant chemoradiation plus radical hysterectomy were retrospectively analyzed. Patients’ tumor biopsy samples were comprehensively profiled using targeted next generation sequencing. Pathologic response to neoadjuvant treatment and DFS were evaluated against the association with genomic traits.
Results:
Genetic alterations of PIK3CA were most frequent (37%), comparable to that of Caucasian populations from The Cancer Genome Atlas. The mutation frequency of genes including TERT, POLD1, NOS2, and FGFR3 was significantly higher in Chinese patients whereas RPTOR, EGFR, and TP53 were underrepresented in comparison to Caucasians. Germline mutations were identified in 21% (13/62) of the cohort and more than half (57%) had mutations in DNA damage repair genes, including BRCA1/2, TP53 and PALB2. Importantly, high tumor mutation burden, TP53 polymorphism (rs1042522), and KEAP1 mutations were found to be associated with poor pathologic response to neoadjuvant chemoradiation treatment. KEAP1 mutations, PIK3CA-SOX2 co-amplification, TERC copy number gain, and TYMS polymorphism correlated with an increased risk of disease relapse.
Conclusion
We report the genomic profile of locally advanced cervical cancer patients and the distinction between Asian and Caucasian cohorts. Our findings highlight genomic traits associated with unfavorable neoadjuvant chemoradiation response and a higher risk of early disease recurrence.
4.Radiation dose and fractionation regimen for limited stage small cell lung cancer: a survey of current practice patterns of Chinese radiation oncologists
Chang XU ; Meng LI ; Ming CHEN ; Shuchai ZHU ; Nan BI ; Xuwei CAI ; Shuanghu YUAN ; Jianzhong CAO ; Xiao HU ; Jiancheng LI ; Wei ZHOU ; Ping WANG ; Jun WANG ; Lujun ZHAO ; Ningbo LIU
Chinese Journal of Radiation Oncology 2023;32(2):93-98
Objective:To investigate the radiation dose and fractionation regimens for limited stage small cell lung cancer (LS-SCLC) in Chinese radiation oncologists.Methods:Over 500 radiation oncologists were surveyed through questionnaire for radiation dose and fractionation regimens for LS-SCLC and 216 valid samples were collected for further analysis. All data were collected by online questionnaire designed by WJX software. Data collection and statistical analysis were performed by SPSS 25.0 statistical software. The differences in categorical variables among different groups were analyzed by Chi-square test and Fisher's exact test. Results:Among 216 participants, 94.9% preferred early concurrent chemoradiotherapy, 69.4% recommended conventional fractionation, 70.8% preferred a total dose of 60 Gy when delivering conventional radiotherapy and 78.7% recommended 45 Gy when administering hyperfractionated radiotherapy.Conclusions:Despite differences in LS-SCLC treatment plans, most of Chinese radiation oncologists prefer to choose 60 Gy conventional fractionated radiotherapy as the main treatment strategy for LS-SCLC patients. Chinese Society of Clinical Oncology (CSCO), National Comprehensive Cancer Network (NCCN) and Chinese Medical Association guidelines or expert consensus play a critical role in guiding treatment decision-making.